Cargando…

Assessment of Relapse in Patients with Schizophrenia during COVID-19 pandemic

INTRODUCTION: People with schizophrenia could be more substantially influenced by the emotional stress brought on by the COVID-19 pandemic, resulting in relapses or worsening of an already existing mental health condition because of the high susceptibility to stress. OBJECTIVES: This study aimed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdelfattah, E., Bassiony, M., Sehlo, M., Zayed, A., Atwa, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9564640/
http://dx.doi.org/10.1192/j.eurpsy.2022.790
_version_ 1784808694875160576
author Abdelfattah, E.
Bassiony, M.
Sehlo, M.
Zayed, A.
Atwa, S.
author_facet Abdelfattah, E.
Bassiony, M.
Sehlo, M.
Zayed, A.
Atwa, S.
author_sort Abdelfattah, E.
collection PubMed
description INTRODUCTION: People with schizophrenia could be more substantially influenced by the emotional stress brought on by the COVID-19 pandemic, resulting in relapses or worsening of an already existing mental health condition because of the high susceptibility to stress. OBJECTIVES: This study aimed to assess the presence of relapse and its risk factors among patients with schizophrenia during the era of COVID 19 pandemic. METHODS: This study included 90 adults who met DSM-5 criteria for schizophrenia and were diagnosed by (SCID-I) Arabic version and who are following up at the outpatient psychiatric clinic, Zagazig University Hospital, Egypt, Positive and Negative Syndrome Scale (PANSS) measuring severity of symptoms, Compliance Rating Scale (CRS) and World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0). scales were conducted on those patients before COVID-19 pandemic from January to April 2019 and repeated on September to November 2020 during COVID 19 pandemic to compare clinical parameters between those two periods as to detect any deterioration in their clinical state. RESULTS: The mean score of compliance rating scale (CRS) was decreased after COVID-19 pandemic compared to before COVID 19 (P<0.001).The mean score of PANSS scale positive subscale (P) had increased after COVID-19 pandemic compared to before COVID 19 (P<0.001). CONCLUSIONS: There was a deterioration of the clinical state of schizophrenic patients during COVID-19 pandemic especially the positive symptoms and following up the news about COVID-19 regularly, decreased level of family support, lower level of compliance with treatment, and having a family member with COVID-19 infection or death were the risk factors for relapse. DISCLOSURE: No significant relationships.
format Online
Article
Text
id pubmed-9564640
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-95646402022-10-17 Assessment of Relapse in Patients with Schizophrenia during COVID-19 pandemic Abdelfattah, E. Bassiony, M. Sehlo, M. Zayed, A. Atwa, S. Eur Psychiatry Abstract INTRODUCTION: People with schizophrenia could be more substantially influenced by the emotional stress brought on by the COVID-19 pandemic, resulting in relapses or worsening of an already existing mental health condition because of the high susceptibility to stress. OBJECTIVES: This study aimed to assess the presence of relapse and its risk factors among patients with schizophrenia during the era of COVID 19 pandemic. METHODS: This study included 90 adults who met DSM-5 criteria for schizophrenia and were diagnosed by (SCID-I) Arabic version and who are following up at the outpatient psychiatric clinic, Zagazig University Hospital, Egypt, Positive and Negative Syndrome Scale (PANSS) measuring severity of symptoms, Compliance Rating Scale (CRS) and World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0). scales were conducted on those patients before COVID-19 pandemic from January to April 2019 and repeated on September to November 2020 during COVID 19 pandemic to compare clinical parameters between those two periods as to detect any deterioration in their clinical state. RESULTS: The mean score of compliance rating scale (CRS) was decreased after COVID-19 pandemic compared to before COVID 19 (P<0.001).The mean score of PANSS scale positive subscale (P) had increased after COVID-19 pandemic compared to before COVID 19 (P<0.001). CONCLUSIONS: There was a deterioration of the clinical state of schizophrenic patients during COVID-19 pandemic especially the positive symptoms and following up the news about COVID-19 regularly, decreased level of family support, lower level of compliance with treatment, and having a family member with COVID-19 infection or death were the risk factors for relapse. DISCLOSURE: No significant relationships. Cambridge University Press 2022-09-01 /pmc/articles/PMC9564640/ http://dx.doi.org/10.1192/j.eurpsy.2022.790 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Abdelfattah, E.
Bassiony, M.
Sehlo, M.
Zayed, A.
Atwa, S.
Assessment of Relapse in Patients with Schizophrenia during COVID-19 pandemic
title Assessment of Relapse in Patients with Schizophrenia during COVID-19 pandemic
title_full Assessment of Relapse in Patients with Schizophrenia during COVID-19 pandemic
title_fullStr Assessment of Relapse in Patients with Schizophrenia during COVID-19 pandemic
title_full_unstemmed Assessment of Relapse in Patients with Schizophrenia during COVID-19 pandemic
title_short Assessment of Relapse in Patients with Schizophrenia during COVID-19 pandemic
title_sort assessment of relapse in patients with schizophrenia during covid-19 pandemic
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9564640/
http://dx.doi.org/10.1192/j.eurpsy.2022.790
work_keys_str_mv AT abdelfattahe assessmentofrelapseinpatientswithschizophreniaduringcovid19pandemic
AT bassionym assessmentofrelapseinpatientswithschizophreniaduringcovid19pandemic
AT sehlom assessmentofrelapseinpatientswithschizophreniaduringcovid19pandemic
AT zayeda assessmentofrelapseinpatientswithschizophreniaduringcovid19pandemic
AT atwas assessmentofrelapseinpatientswithschizophreniaduringcovid19pandemic